To date, the literature has focused on whether IgLON5-IgG disease is a primary neurodegenerative process with a secondary inflammatory response against IgLON5 or a primary autoimmune process driven by pathogenic IgLON5-IgG with subsequent neurodegeneration. This evidence concerns the gene IGLON5 and glycogen storage disease VI.